TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11194695

Group type: EXPERIMENTAL
Intervention: Self-help booklet promoting dietary change delivered by physicians
Number of subjects: 935

Group type: COMPARATOR
Intervention: Self-help booklet promoting dietary change delivered by clinic staff
Number of subjects: 935
Study: 9062602

Group type: EXPERIMENTAL
Intervention: Pethidine (0.1 ml, 10 mg/ml) combined with lidocaine (3 ml, 2%)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (0.1 ml) combined with lidocaine (3 ml, 2%)
Number of subjects: 80
Study: 7870908

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 3739810

Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cue avoidance
Number of subjects: 53

Group type: COMPARATOR
Intervention: Social pressure
Number of subjects: 53
Study: 30227890

Group type: EXPERIMENTAL
Intervention: Optimised participant information brochure and cover letter
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Control group: original participant information brochure and accompanying letter
Number of subjects: 2262
Study: 27912943

Group type: EXPERIMENTAL
Intervention: High-speed yoga (HSY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-speed yoga (SSY)
Number of subjects: 0
Study: 24621557

Group type: EXPERIMENTAL
Intervention: Trial exclusion criteria
Number of subjects: 15379

Group type: EXPERIMENTAL
Intervention: Other criteria (including comorbid conditions)
Number of subjects: 15379

Group type: EXPERIMENTAL
Intervention: No reason provided
Number of subjects: 15379
Study: 22734388

Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Blood Pricking
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined Therapy (Acupotomy + Blood Pricking)
Number of subjects: 90
Study: 20668051

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg Ca/d from 20 weeks of gestation until delivery)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 18346640

Group type: EXPERIMENTAL
Intervention: anti-CD25 monoclonal antibody (Daclizumab)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 15866629

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg before transplantation and 20 mg on day 4)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no basiliximab)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Basiliximab (when excluding non-heart-beating donors)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (when excluding non-heart-beating donors)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 87
Study: 11956046

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg qid for 1 week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol 100, 100, and 200 microg inhaled at 5-minute intervals after exercise
Number of subjects: 8
Study: 9557918

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 245

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 245
Study: 7636536

Group type: EXPERIMENTAL
Intervention: Dexverapamil 120 mg/m2 plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dexverapamil 180 mg/m2 plus dexamethasone plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Number of subjects: 23
Study: 2129695

Group type: EXPERIMENTAL
Intervention: Counseling and follow-up at 2 and 3 weeks and at 3 and 6 months (group B)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Counseling alone (group A)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Counseling by smoking physicians
Number of subjects: 152

Group type: COMPARATOR
Intervention: Counseling by non-smoking physicians
Number of subjects: 152
Study: 326013

Group type: EXPERIMENTAL
Intervention: 1 Gm. of ASA daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ASA
Number of subjects: 148
Study: 29373530

Group type: EXPERIMENTAL
Intervention: High fiber scone with RS4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fiber control scone without RS4
Number of subjects: 0
Study: 26536443

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive-behavioral therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study: 24308723

Group type: EXPERIMENTAL
Intervention: Long-acting testosterone undecanoate (TU) 1,000 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 23346766

Group type: EXPERIMENTAL
Intervention: Group IV (20 ml dexamethasone at 0.5 mg/ml, injected over 30s)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Group I (2 ml dexamethasone at 5 mg/ml, injected over 5s)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Group II (4 ml dexamethasone at 2.5 mg/ml, injected over 5s)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Group III (10 ml dexamethasone at 1 mg/ml, injected over 5s)
Number of subjects: 400
Study: 20516633

Group type: EXPERIMENTAL
Intervention: Etidronate (20 mg/kg/day for 12 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Indomethacin (75 mg/day for 2 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 52
Study: 18612156

Group type: EXPERIMENTAL
Intervention: Capecitabine as second treatment (1,250 mg/m² twice daily, days 1 through 14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Capecitabine as first treatment (1,250 mg/m² twice daily, days 1 through 14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FU/LV as first treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FU/LV as second treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Number of subjects: 40
Study: 16021114

Group type: EXPERIMENTAL
Intervention: Educational videotape
Number of subjects: 217

Group type: COMPARATOR
Intervention: Traditional clinic visit
Number of subjects: 217
Study: 11936398

Group type: EXPERIMENTAL
Intervention: External neurolysis of the lingual nerve
Number of subjects: 10
Study: 10558962

Group type: EXPERIMENTAL
Intervention: GM-CSF 80 microgram
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GM-CSF 250 microgram
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 8919382

Group type: EXPERIMENTAL
Intervention: Fascial stapler technique
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional sutured technique
Number of subjects: 38
Study: 2060447

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation for 10 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 18
Study: 6313458

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice a day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cimetidine, 200 mg three times a day and 400 mg at night
Number of subjects: 44
Study: 31872869

Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: D3 dissection
Number of subjects: 99
Study: 30575979

Group type: EXPERIMENTAL
Intervention: Ego depletion (experimental group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 29208190

Group type: EXPERIMENTAL
Intervention: Three-session, manualised, psychosocial, gender-specific group intervention plus BBV transmission information booklet and treatment as usual (TAU)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Information booklet plus treatment as usual (TAU)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Three-session, manualised, psychosocial, gender-specific group intervention
Number of subjects: 176
Study: 24494935

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: WOMAC pain subscale
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: WOMAC function scale
Number of subjects: 63
Study: 24378255

Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 221
Study: 22565002

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d plus Everolimus 10 mg/d
Number of subjects: 111

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d alone
Number of subjects: 111
Study: 21163014

Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation training
Number of subjects: 59
Study: 17469692

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (especially donepezil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMDA receptor antagonist (memantine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 16035127

Group type: EXPERIMENTAL
Intervention: Timed bright light therapy (morning or afternoon exposure at > or = 2500 lux)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual indoor light (150-200 lux)
Number of subjects: 70
Study: 11831542

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/325 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxycodone 7.5 mg/500 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/650 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 10030391

Group type: EXPERIMENTAL
Intervention: Palmitic acid diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lauric acid diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Saturated diets (lauric and palmitic)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standardized diets
Number of subjects: 32
Study: 7541269

Group type: EXPERIMENTAL
Intervention: CY mobilized PBPC
Number of subjects: 30
Study: 2188165

Group type: EXPERIMENTAL
Intervention: Sublingual captopril (SLC) 25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sublingual nifedipine (SLN) 10 mg
Number of subjects: 40
Study: 6633598

Group type: COMPARATOR
Intervention: Blinded randomization
Number of subjects: 145

Group type: COMPARATOR
Intervention: Unblinded randomization
Number of subjects: 145

Group type: COMPARATOR
Intervention: Nonrandomized studies
Number of subjects: 145
Study: 31253599

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 84
Study: 28917493

Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial annular velocity (MAV) changes in e'
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial annular velocity (MAV) changes in s'
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial annular velocity (MAV) changes in a'
Number of subjects: 224
Study: 27624720

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT) post-arthroplasty at 10 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT) post-arthroplasty at 26 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Agreement between anchor- and distribution-based methods
Number of subjects: 380
Study: 24218432

Group type: EXPERIMENTAL
Intervention: Amlodipine±perindopril
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Atenolol±bendroflumethiazide
Number of subjects: 1006
Study: 18827360

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) formulations of glipizide (fast, moderate, slow)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of glipizide
Number of subjects: 6
Study: 15465619

Group type: EXPERIMENTAL
Intervention: Education and referral intervention program initiated by community pharmacists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (written asthma information, referral to a respiratory therapist, usual pharmacy and physician care)
Number of subjects: 0
Study: 10688396

Group type: EXPERIMENTAL
Intervention: Etanercept 10 mg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 9239453

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 30
Study: 8325622

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg and then 1 mg/4 hr over 24 hr) and transdermal nitroglycerin (10 mg/12 hr over 24 hr)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Octreotide (continuous intravenous infusion of 25 micrograms/hr over 12 hr and then 100 micrograms at hr 12 and hr 18 subcutaneously)
Number of subjects: 87
Study: 3716920

Group type: EXPERIMENTAL
Intervention: Experimental group (children who saw videotaped television programs with drinking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children who saw videotaped television programs without drinking)
Number of subjects: 0
Study: 30374950

Group type: EXPERIMENTAL
Intervention: TEDA with bupivacaine (B-group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (P-group)
Number of subjects: 19
Study: 27807890

Group type: EXPERIMENTAL
Intervention: 150 mg extended-release aspirin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 26681730

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1375
Study: 24375476

Group type: EXPERIMENTAL
Intervention: Topical anesthetic application for 30 minutes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Topical anesthetic application for 60 minutes
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no hydration)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Topical anesthetic application for 30 minutes vs 60 minutes
Number of subjects: 4
Study: 23250175

Group type: EXPERIMENTAL
Intervention: Preprocedural mouthrinsing with 0.2% chlorhexidine gluconate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High volume evacuator attachment during ultrasonic scaling
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of preprocedural mouthrinsing with 0.2% chlorhexidine gluconate and high volume evacuator attachment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (ultrasonic scaling without rinsing or suction)
Number of subjects: 90
Study: 19846028

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0
Study: 17236796

Group type: EXPERIMENTAL
Intervention: Capsaicin exposure (5-200 microM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Capsaicin exposure (50 microM and above)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Capsaicin exposure (all concentrations)
Number of subjects: 36
Study: 15000501

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg ethanol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 34
Study: 11602546

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for 3 months)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 63
Study: 9222303

Group type: EXPERIMENTAL
Intervention: Screening group (serum AFP and real-time ultrasound every 6 months)
Number of subjects: 18820

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 18820
Study: 7584258

Group type: EXPERIMENTAL
Intervention: Auditory stimuli (spoken words in male voice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimuli (written words)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory stimuli (words spoken in female voice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimuli (digits shown in one location)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimuli (digits shown in another location)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory stimuli (sounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimuli (pictures)
Number of subjects: 0
Study: 3038422

Group type: EXPERIMENTAL
Intervention: Sublingual captopril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral captopril
Number of subjects: 40
Study: 29620995

Group type: EXPERIMENTAL
Intervention: 3 months of modified FOLFOX6 (mFOLFOX6)
Number of subjects: 2010

Group type: COMPARATOR
Intervention: 6 months of modified FOLFOX6 (mFOLFOX6)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX
Number of subjects: 2010

Group type: COMPARATOR
Intervention: 6 months of CAPOX
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: 3 months of mFOLFOX6
Number of subjects: 2010

Group type: COMPARATOR
Intervention: 6 months of mFOLFOX6
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 in T4 and/or N2 population
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 in T1-3N1 population
Number of subjects: 2010
Study: 27617366

Group type: EXPERIMENTAL
Intervention: One of four text versions of a warning label (e.g., SAFETY WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay)
Number of subjects: 2202

Group type: COMPARATOR
Intervention: No warning label
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: One of four text versions of a warning label
Number of subjects: 2202
Study: 24899156

Group type: EXPERIMENTAL
Intervention: Fresh avocado (23 g of lipid) with high-β-carotene tomato sauce (33.7 mg of β-carotene)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fresh avocado (23 g of lipid) with raw carrots (27.3 mg of β-carotene and 18.7 mg of α-carotene)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fresh avocado (23 g of lipid)
Number of subjects: 12
Study: 21721947

Group type: EXPERIMENTAL
Intervention: Resin group (bonded with two-step bonding resin, Optibond FL, and Tetric EvoFlow)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonresin group (bonded without applying Optibond FL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonresin group
Number of subjects: 52
Study: 20840515

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (saline of equal volume)
Number of subjects: 42
Study: 18022349

Group type: EXPERIMENTAL
Intervention: Bioresorbable mini-plate fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium mini-plate fixation
Number of subjects: 40
Study: 15935646

Group type: EXPERIMENTAL
Intervention: Group A: CI 10 mL/h, PCEA bolus 6 mL, 8‐min lockout
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group B: CI 10 mL/h, PCEA bolus 12 mL, 16‐min lockout
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group C: CI 15 mL/h, PCEA bolus 6 mL, 8‐min lockout
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group D: CI 15 mL/h, PCEA bolus 12 mL, 16‐min lockout
Number of subjects: 220

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 220
Study: 14646369

Group type: EXPERIMENTAL
Intervention: Urinary sediment podocalyxin (u-sed-PCX) measured by ELISA in children with glomerular diseases (group I and II)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Urinary sediment podocalyxin (u-sed-PCX) in group I (inflammatory glomerular diseases)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation of proteinuria with u-sed-PCX in group I
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Comparison of u-sed-PCX levels in acute vs chronic phase in group I
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation of u-sed-PCX with histological findings in renal biopsies
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Persistent high level of u-sed-PCX
Number of subjects: 111
Study: 11140343

Group type: EXPERIMENTAL
Intervention: Engagement services during the intake period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tangible engagement services provided to women during the intake period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study: 8988070

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral prednisolone (30 mg once daily)
Number of subjects: 19
Study: 1455272

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Propofol and Midazolam
Number of subjects: 0
Study: 6738029

Group type: EXPERIMENTAL
Intervention: Stutterers
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonstutterers (Control)
Number of subjects: 14
Study: 29878869

Group type: EXPERIMENTAL
Intervention: 400 µg salbutamol administered before exercise
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with asthma
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study: 27559041

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose / 10 mg maintenance dose once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ticagrelor (180 mg loading dose / 90 mg maintenance dose twice daily)
Number of subjects: 50
Study: 25344328

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg plus standard treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Matched placebo plus standard treatment
Number of subjects: 108
Study: 22907057

Group type: EXPERIMENTAL
Intervention: High-sodium diet (HS; 350 mmol day(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) during high-sodium diet
Number of subjects: 12
Study: 19876001

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) diet
Number of subjects: 164

Group type: COMPARATOR
Intervention: Carbohydrate (CARB) diet
Number of subjects: 164

Group type: COMPARATOR
Intervention: Protein (PROT) diet
Number of subjects: 164